Efficacy and safety results from IMblaze370, a randomised Phase III study comparing atezolizumab plus cobimetinib and atezolizumab monotherapy vs regorafenib in chemotherapy-refractory metastatic colorectal cancer

被引：27

作者：

Bendell, J. ^{[1
]}

Ciardiello, F. ^{[2
]}

Tabernero, J. ^{[3
]}

Tebbutt, N. ^{[4
]}

Eng, C. ^{[5
]}

Di Bartolomeo, M. ^{[6
]}

Falcone, A. ^{[7
]}

Fakih, M. ^{[8
]}

Kozloff, M. ^{[9
]}

Segal, N. ^{[10
]}

Sobrero, A. ^{[11
]}

Shi, Y. ^{[12
]}

Roberts, L. ^{[12
]}

Yan, Y. ^{[12
]}

Chang, I. ^{[12
]}

Uyei, A. ^{[12
]}

Kim, T. ^{[13
]}

机构：

[1] Sarah Cannon Res Inst Tennessee Oncol, Nashville, TN USA

[2] Univ Campania Luigi Vanvitelli, Naples, Italy

[3] VHIO, Barcelona, Spain

[4] Austin Hlth, Med Oncol, Heidelberg, Vic, Australia

[5] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA

[6] Fdn IRCCS Ist Nazl Tumori, Milan, Italy

[7] Univ Hosp Pisa, Pisa, Italy

[8] City Hope Natl Med Ctr, Duarte, CA USA

[9] Univ Chicago, Chicago, IL 60637 USA

[10] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA

[11] IRCCS Osped San Martino IST, Genoa, Italy

[12] Genentech Inc, San Francisco, CA 94080 USA

[13] Univ Ulsan, Asan Med Ctr, Seoul, South Korea

来源：

关键词：

D O I：

10.1093/annonc/mdy208.003

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

LBA - 004

引用

页码：123 / 123

页数：1